Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional survey - 21/07/22
, Farzana Ismail, MMed c, d, †, Martie Van der Walt, PhD e, †, Nazir Ismail, FCPath f, Nkateko Mkhondo, MPH g, Sicelo Dlamini, MPH h, Thuli Mthiyane, PhD e, Jeremiah Chikovore, PhD a, Olanrewaju Oladimeji, PhD a, David Mametja, MPH i, Phaleng Maribe, BPhil e, Ishen Seocharan, BTech e, Phumlani Ximiya, BA h, Irwin Law, MBBS f, Marina Tadolini, MD j, k, Khangelani Zuma, PhD a, Samuel Manda, PhD e, Charalambos Sismanidis, PhD f, Yogan Pillay, PhD l, Lindiwe Mvusi, MBChB hSummary |
Background |
Tuberculosis remains an important clinical and public health issue in South Africa, which has one of the highest tuberculosis burdens in the world. We aimed to estimate the burden of bacteriologically confirmed pulmonary tuberculosis among people aged 15 years or older in South Africa.
Methods |
This multistage, cluster-based, cross-sectional survey included eligible residents (age ≥15 years, who had slept in a house for ≥10 nights in the preceding 2 weeks) in 110 clusters nationally (cluster size of 500 people; selected by probability proportional-to-population size sampling). Participants completed face-to-face symptom questionnaires (for cough, weight loss, fever, and night sweats) and manually read digital chest X-ray screening. Screening was recorded as positive if participants had at least one symptom or an abnormal chest X-ray suggestive of tuberculosis, or a combination thereof. Sputum samples from participants who were screen-positive were tested by the Xpert MTB/RIF Ultra assay (first sample) and Mycobacteria Growth Indicator Tube culture (second sample), with optional HIV testing. Participants with a positive Mycobacterium tuberculosis complex culture were considered positive for bacteriologically confirmed pulmonary tuberculosis; when culture was not positive, participants with a positive Xpert MTB/RIF Ultra result with an abnormal chest X-ray suggestive of active tuberculosis and without current or previous tuberculosis were considered positive for bacteriologically confirmed pulmonary tuberculosis.
Findings |
Between Aug 15, 2017, and July 28, 2019, 68 771 people were enumerated from 110 clusters, with 53 250 eligible to participate in the survey, of whom 35 191 (66·1%) participated. 9066 (25·8%) of 35 191 participants were screen-positive and 234 (0·7%) were identified as having bacteriologically confirmed pulmonary tuberculosis. Overall, the estimated prevalence of bacteriologically confirmed pulmonary tuberculosis was 852 cases (95% CI 679–1026) per 100 000 population; the prevalence was highest in people aged 35–44 years (1107 cases [95% CI 703–1511] per 100 000 population) and those aged 65 years or older (1104 cases [680–1528] per 100 000 population). The estimated prevalence was approximately 1·6 times higher in men than in women (1094 cases [95% CI 835–1352] per 100 000 population vs 675 cases [494–855] per 100 000 population). 135 (57·7%) of 234 participants with tuberculosis screened positive by chest X-ray only, 16 (6·8%) by symptoms only, and 82 (35·9%) by both. 55 (28·8%) of 191 participants with tuberculosis with known HIV status were HIV-positive.
Interpretation |
Pulmonary tuberculosis prevalence in this survey was high, especially in men. Despite the ongoing burden of HIV, many participants with tuberculosis in this survey did not have HIV. As more than half of the participants with tuberculosis had an abnormal chest X-ray without symptoms, prioritising chest X-ray screening could substantially increase case finding.
Funding |
Global Fund, Bill & Melinda Gates Foundation, USAID.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 8
P. 1172-1180 - août 2022 Retour au numéro
Article précédent
- Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study
- J Daniel Kelly, Collin Van Ryn, Moses Badio, Tamba Fayiah, Kumblytee Johnson, Dehkontee Gayedyu-Dennis, Sheri D Weiser, Travis C Porco, Jeffery N Martin, Michael C Sneller, George W Rutherford, Cavan Reilly, Mosoka P Fallah, J Soka Moses
- Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial
- Olivier Segeral, Bunnet Dim, Christine Durier, Sovann Nhoueng, Kearena Chhim, Saren Sovann, Sophal Yom, Chanlina Vong, Song Yin, Bandith Ros, Vutha Ky, Sothy Pech, Bunthoeun Nem, Kay Hout, Julia Guillebaud, Eamkim Ear, Layana Caroupaye-Caroupin, Claire Rekacewicz, Laura Fernandez, Denis Laurent, Chantana Yay, Rattana Kim, Laurence Meyer, Samsorphea Chhun, Laurence Borand for the ANRS-MIE TA PROHM Study Group, Chanthy Keang, Ousa Khan, Boraneath Nang, Vouch Leang Sreng, Sopheavet In, Sineath Sun, Linda Sov, Bunrachana Nor, Brembrey Hing, Sokkim Seng, Sophea Soum, Leakhena Say, Sao Sarady Ay, Daneth Thol, Chhorn Chhouk, Patrice Piola, Janin Nouhin, Anne-Marie Roque Afonso, Jean Charles Duclos Vallee, Channa Sann, Leang Sim Kruy, Maud Lemoine, Laurent Mandelbrot, Stephane Blanche, Alpha Diallo, Christelle Paul, SAY Tiv, Polinn Sar, Lyvoin Nov, Darapoline Vann, Tha Chea, Bunrith Touch, Kongkea Neav, Ekvitou Kong, Ratha Chea, Chanksolina Ouk, Lyhour Meak, Rayounette Krouch, Naneth Chhan, Sody Seang, Veasna Nuon, Leang Meng, Sok Leakhena Tharith, Sovannara Hang, Vanrithy Som, Rithy Som, Phirak Seng, Malys Lim, Kimchhorn Srey, Sok Rothavy Uch, Pichthyda Hou, Satha Bo, Eanghor Ieang, Kimchhorng Korn, Chan Reatrey Noun, Sokhoeun Soy, Thou Khim, Vutha Sou, Sokha Pol, Samreth Nget, Marina Sun, Phearom Uon, Kim Teng Ya, Kimsreng Lean, Kim Ean Eang, Sophal Ung, Rauin Rith, Charya Mom, Chanthea Keang, Soklyda Sam, Sokneth Chuong, Chanmony Nam, Sophya Khuon, Sidet Cheang, Sopheak Lean, Arnaud Tarantola, Isabelle Fournier, Nicolas Rouveau, Maria-Camila Calvo cortez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?